top of page

Janssen - Fate Therapeutics iPSC CAR NK and CAR-T Collaboration

Sexton Riley LLP Represents Janssen in Worldwide Collaboration Agreement with Fate Therapeutics for Novel iPSC-derived Cell-based Cancer Immunotherapies

April 2020

​Sexton Riley LLP represented Janssen Biotech, Inc., an affiliate of Johnson & Johnson, in its global collaboration and option agreement with Fate Therapeutics, Inc., to research and develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates for the treatment of hematologic malignancies and solid tumors.

Fate Therapeutics' press release is here.


bottom of page